Aventis sells U.S. API business to German biotech company

German biotech company Girindus AG (Bensberg, Germany) has agreed to purchase Aventis Pharmaceuticals Inc.'s (Bridgewater, NJ) active pharmaceuticals ingredients (API) business based in Cincinnati. Girindus plans to assume control of the plant by the end of the year. A purchase price had not yet been reached.

Under the proposed deal, Girindus would produce APIs in Cincinnati for Aventis Pharmaceuticals for the next three years. Aventis Pharmaceuticals would then consider developing a long-term outsourcing partnership with Girindus.

"The intended acquisition is a major milestone in the Girindus expansion strategy to strengthen U.S. market presence," the company said.

Aventis Pharmaceuticals, the U.S. subsidiary of European life sciences company Aventis, is involved in the development, manufacturing, and marketing of pharmaceutical products.

Girindus is involved in the development of biotech and chemical processes, and the scale-up and commercial production of active pharmaceutical ingredients.

For more information, contact Girindus' U.S. sales office at 727-781-8383.

Edited by Jim Pomager
Assistant Editor, Pharmaceutical Online